A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.
Researchers find that most psychiatric drugs cause severe withdrawal despite attempt s to gradually decrease the dosage.
A friend said to me recently, "Oh, he suffered such a lot. That’s over for him." I know their words were intended to comfort me over my son’s suicide. Our fine, excellent son, Abraham, had committed suicide a month before Christmas 2019. Nevertheless, I bridled inwardly at the suggestion, not wanting to remember Abraham as merely the sum of his sufferings—he was so much more than that.
A new review of antipsychotic trials conducted over the last 24 years finds that the placebo response rate is steadily increasing, and drug response is decreasing.
A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.
A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.
A new study finds that clinicians’ disregard for mental health patients’ insight into their own condition may be detrimental to treatment.
Experts across the globe point to the harms of drug companies’ influence on research, practice, and education in healthcare noting that it compromises patient care.
A new special issue brings together articles exploring the harmful effects of simultaneous multiple medication use.
A new article explores how psychiatric diagnoses are differentially applied to people of different racial and class backgrounds.
Increased Parkinson's risk could be related to lithium, antipsychotic, and antiepileptic drug use.
A new attempt to study the neurological effects of long-term exposure to antipsychotics uses healthy volunteers on minimal doses for 15 days.
The approval of the digital antipsychotic may open the door for more pharmaceutical company profits without evidence of benefits to patients.
A study, recently published in Psychological Medicine, examined the cognitive functioning of individuals with schizophrenia who discontinued antipsychotics, and those who maintained their antipsychotic...
People who take anticholinergic drugs, such as antidepressants and antipsychotics, are at a 50% higher risk of dementia.
A new study has found that of 10 people who were fully recovered from their first episode of schizophrenia (FES), those not taking antipsychotics did better in terms of cognitive, social, and role functioning—and reached full recovery more quickly.
A new study has found that children and adolescents taking a high dose of antipsychotics are almost twice as likely to die of any cause than children on other types of medications.
Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.
Mixed-Methods study explores the experiences of antipsychotic discontinuation among service users.
A new analysis of antipsychotic treatment of schizophrenia (published in Schizophrenia Bulletin) has found that two-thirds of patients treated this way do not experience symptom remission.
A systematic review of the limited research available on the long-term effects of antipsychotics finds fewer symptoms in those off of the drugs.
Researchers review the risks and benefits of deprescribing from antipsychotic drugs and advocate for a patient-centered approach to tapering.
People who reduced antipsychotic use by tapering were doing just as well after five years as those who continued using the drugs.
New intervention shows promise in reducing over-prescription of off-label antipsychotics in older adults.